Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure
Emerson C. Perin,Hans F. Dohmann,Radovan Borojevic,Suzana A. Silva,Andre L.S. Sousa,Claudio Tinoco Mesquita,Maria Isabel D. Rossi,Antonio Carlos Carvalho,Hélio S. Dutra,Hans J.F. Dohmann,Guilherme V. Silva,Luciano Belem,Ricardo Vivacqua,Fernando Oswaldo Dias Rangel,Roberto Esporcatte,Yong-Jian Geng,William K. Vaughn,Joao A.R. Assad,Evandro Tinoco Mesquita,James T. Willerson +19 more
Reads0
Chats0
TLDR
The present study demonstrates the relative safety of intramyocardial injections of bone marrow–derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.Abstract:
Background— This study evaluated the hypothesis that transendocardial injections of autologous mononuclear bone marrow cells in patients with end-stage ischemic heart disease could safely promote neovascularization and improve perfusion and myocardial contractility. Methods and Results— Twenty-one patients were enrolled in this prospective, nonrandomized, open-label study (first 14 patients, treatment; last 7 patients, control). Baseline evaluations included complete clinical and laboratory evaluations, exercise stress (ramp treadmill), 2D Doppler echocardiogram, single-photon emission computed tomography perfusion scan, and 24-hour Holter monitoring. Bone marrow mononuclear cells were harvested, isolated, washed, and resuspended in saline for injection by NOGA catheter (15 injections of 0.2 cc). Electromechanical mapping was used to identify viable myocardium (unipolar voltage ≥6.9 mV) for treatment. Treated and control patients underwent 2-month noninvasive follow-up, and treated patients alone underwen...read more
Citations
More filters
Journal ArticleDOI
Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?
TL;DR: Whether monocytes represent deteriorating immune overreaction in heart failure (HF), or a desperate attempt for tissue repair or physiological compensation in the failing heart, is provided.
Journal ArticleDOI
Can stem cells mend a broken heart
TL;DR: This review details recent experimental data and discusses the clinical potential of the various stem cell sources for CCT, including embryonic or foetal stem cells, myoblasts, and bone marrow stem cells.
Journal ArticleDOI
Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.
Mariell Jessup,Nicholas Banner,Susan C. Brozena,Carlo Campana,Angelika Costard-Jäckle,Thomas J. Dengler,Sharon A. Hunt,Marco Metra,Axel O. Rahmel,Dale G. Renlund,Heather J. Ross,Lynne W. Stevenson +11 more
Journal ArticleDOI
Stem cell therapy for ischemic heart disease.
Rutger J. Hassink,Joshua D. Dowell,Aart Brutel de la Rivière,Pieter A. Doevendans,Loren J. Field +4 more
TL;DR: Surprisingly, the observation that non-cardiomyogenic cells could also improve cardiac function indicates that functional integration of donor cells might not be required to achieve a beneficial effect.
Patent
Methods and compositions for treating tissue using silk proteins
TL;DR: In this paper, a self-reinforcing composite biomatrix, methods of manufacture and use, and Kits including delivery devices suitable for delivering the compositions are also disclosed, in some embodiments, the composition can include at least three components.
References
More filters
Journal ArticleDOI
Isolation of putative progenitor endothelial cells for angiogenesis.
Takayuki Asahara,Toyoaki Murohara,Alison Sullivan,Marcy Silver,Rien van der Zee,Tong Li,Bernhard Witzenbichler,Gina C. Schatteman,Jeffrey M. Isner +8 more
TL;DR: It is suggested that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarianAngiogenesis.
Journal ArticleDOI
Bone marrow cells regenerate infarcted myocardium
Donald Orlic,Jan Kajstura,Stefano Chimenti,Igor Jakoniuk,Stacie M. Anderson,Baosheng Li,James Pickel,Ronald D.G. McKay,Bernardo Nadal-Ginard,David M. Bodine,Annarosa Leri,Piero Anversa +11 more
TL;DR: It is indicated that locally delivered bone marrow cells can generate de novo myocardium, ameliorating the outcome of coronary artery disease.
Journal ArticleDOI
Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
Alfred Kocher,Michael D. Schuster,Matthias Szabolcs,Shin Takuma,Daniel Burkhoff,Jennifer Wang,Shunichi Homma,Niloo M. Edwards,Silviu Itescu +8 more
TL;DR: It is shown that bone marrow from adult humans contains endothelial precursors with phenotypic and functional characteristics of embryonic hemangioblasts, and that these can be used to directly induce new blood vessel formation in the infarct-bed and proliferation of preexisting vasculature after experimental myocardial infarction.
Journal ArticleDOI
ACC/AHA 2002 Guideline Update for Exercise Testing: Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines)
Raymond J. Gibbons,Gary J. Balady,J. Timothy Bricker,Bernard R. Chaitman,Gerald F. Fletcher,Victor F. Froelicher,Daniel B. Mark,Ben D. McCallister,Aryan N. Mooss,Michael G. O’Reilly,William L. Winters,Elliott M. Antman,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Richard O. Russell,Sidney C. Smith +19 more
TL;DR: The American College of Cardiology (ACC)/AHA Task Force on Practice Guidelines regularly reviews existing guidelines to determine when an update or full revision is needed.
Journal ArticleDOI
Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart
TL;DR: The persistence of the engrafted hMSCs and their in situ differentiation in the heart may represent the basis for using these adult stem cells for cellular cardiomyoplasty.